Research output: Contribution to journal › Review article › peer-review
Boron neutron capture therapy: Current status and future perspectives. / Dymova, Mayya Alexandrovna; Taskaev, Sergey Yurjevich; Richter, Vladimir Alexandrovich et al.
In: Cancer Communications, Vol. 40, No. 9, 01.09.2020, p. 406-421.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Boron neutron capture therapy: Current status and future perspectives
AU - Dymova, Mayya Alexandrovna
AU - Taskaev, Sergey Yurjevich
AU - Richter, Vladimir Alexandrovich
AU - Kuligina, Elena Vladimirovna
N1 - Funding Information: This study was supported by the Russian Science Foundation (project No. 19‐72‐30005) and the Russian State funded budget project (ICBFM SB RAS АААА‐А17‐117020210023‐1). Publisher Copyright: © 2020 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - The development of new accelerators has given a new impetus to the development of new drugs and treatment technologies using boron neutron capture therapy (BNCT). We analyzed the current status and future directions of BNCT for cancer treatment, as well as the main issues related to its introduction. This review highlights the principles of BNCT and the key milestones in its development: new boron delivery drugs and different types of charged particle accelerators are described; several important aspects of BNCT implementation are discussed. BCNT could be used alone or in combination with chemotherapy and radiotherapy, and it is evaluated in light of the outlined issues. For the speedy implementation of BCNT in medical practice, it is necessary to develop more selective boron delivery agents and to generate an epithermal neutron beam with definite characteristics. Pharmacological companies and research laboratories should have access to accelerators for large-scale screening of new, more specific boron delivery agents.
AB - The development of new accelerators has given a new impetus to the development of new drugs and treatment technologies using boron neutron capture therapy (BNCT). We analyzed the current status and future directions of BNCT for cancer treatment, as well as the main issues related to its introduction. This review highlights the principles of BNCT and the key milestones in its development: new boron delivery drugs and different types of charged particle accelerators are described; several important aspects of BNCT implementation are discussed. BCNT could be used alone or in combination with chemotherapy and radiotherapy, and it is evaluated in light of the outlined issues. For the speedy implementation of BCNT in medical practice, it is necessary to develop more selective boron delivery agents and to generate an epithermal neutron beam with definite characteristics. Pharmacological companies and research laboratories should have access to accelerators for large-scale screening of new, more specific boron delivery agents.
KW - boron compounds
KW - Boron neutron capture therapy
KW - cancer
KW - cancer treatment
KW - drug delivery
KW - EPITHERMAL NEUTRON
KW - BNCT
KW - CLINICAL-TRIAL
KW - DNA-DAMAGE
KW - MALIGNANT PLEURAL MESOTHELIOMA
KW - BLOOD-BRAIN-BARRIER
KW - NECK-CANCER
KW - IN-VITRO
KW - RECURRENT HEAD
KW - SQUAMOUS-CELL CARCINOMA
UR - http://www.scopus.com/inward/record.url?scp=85089454654&partnerID=8YFLogxK
U2 - 10.1002/cac2.12089
DO - 10.1002/cac2.12089
M3 - Review article
C2 - 32805063
AN - SCOPUS:85089454654
VL - 40
SP - 406
EP - 421
JO - Cancer Communications
JF - Cancer Communications
SN - 2523-3548
IS - 9
ER -
ID: 24986310